Avantor, Inc. (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries. The company offers a wide range of products, including laboratory supplies, chemicals, and equipment. Avantor competes with other major players in the industry, such as Thermo Fisher Scientific and Merck KGaA.
On October 30, 2025, SUMME GREGORY L, a director at Avantor, made a significant purchase of 100,000 shares of the company's common stock at $11.25 per share. This transaction increased his total holdings to 300,000 shares. This move comes amid a challenging period for Avantor, as the company recently reported disappointing third-quarter financial results.
Avantor's third-quarter 2025 financial performance fell short of expectations, leading to a notable decline in its stock price. The company's adjusted earnings per share (EPS) decreased by 15.4% year-over-year to $0.22, missing the Zacks Consensus Estimate by 4.4%. Additionally, Avantor reported a GAAP loss per share of $1.04, compared to an EPS of $0.08 in the same quarter last year.
Revenues for the quarter totaled $1.62 billion, representing a 5.3% decline from the previous year and falling short of the Zacks Consensus Estimate by 1.6%. The company's core segments both posted declines, contributing to the overall revenue drop. Foreign currency translation had a positive impact of 2.2%, while mergers and acquisitions negatively impacted revenue by 2.8%, leading to a 4.7% decline in organic sales.
In response to these results, Avantor revised its full-year 2025 guidance, projecting EPS to be between $0.88 and $0.92, with organic sales expected to decrease by up to 3.5%. The disappointing financial performance led to a 23.2% plunge in Avantor's stock price. As highlighted by JPMorgan Chase and Co., the price target for Avantor was adjusted from $17.00 to $14.00.
